Skip to main content

Table 4 Cumulative effect analysis by the number of unfavorable genotypes in miRNA biogenesis pathway genes and disease free survival

From: Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival

Number of unfavorable genotypes Disease-free survival
Cases, N a (%) Relapse, N (%) aHRb (95 % CI) P
0-2 163 (35.4) 18 (21.4) 1 (reference)  
3 188 (40.9) 32 (38.1) 2.16(1.18- 3.93) 1.22E-02
4-6 109 (23.7) 34 (40.5) 4.47(2.45- 8.14) 9.87E-07
P trend    2.11(1.57- 2.83) 6.11E-07
  Overall survival
  Cases, N a (%) Death, N (%) aHR c (95 % CI) P
0-2 6 (14.6) 124 (26.4) 1 (reference)  
3 12 (29.3) 214 (45.5) 1.21(0.44- 3.30) 7.13E-01
4-5 23 (56.1) 132 (28.1) 5.34(2.12-13.49) 3.93E-04
P trend    2.80(1.72- 4.55) 3.30E-05
  1. NOTE Unfavorable genotypes were defined as rs2292779 (GG), rs11786030 (AG + GG), rs9606250 (AA + AT), rs1057035 (TC + CC), rs4759659 (GG + GA), and rs11060845 (TT) for disease-free survival and rs2292779 (GG), rs11786030 (AG + GG), rs1057035 (TC + CC), rs874332 (CC), and rs4968104 (TT) for overall survival, respectively.
  2. a Due to excluding the subject which has at least one missing genotype information in this analysis, all subjects are less than 480 for disease-free survival and 488 for overall survival.
  3. b Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative) and hormone receptor therapy (yes and no).
  4. c Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), metastasis (no and yes), histologic grade (I-II and III), and hormone receptor therapy (yes and no).